Nanomedicine News

RSS

Celator to Present at 2014 BIO International Convention and 9th Annual JMP Healthcare Conference

Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the company's management team will present at the following conferences in June:

18 Jun 2014

Avidity NanoMedicines’ Antibody-siRNA Complex Technology Awarded Two US Patents

Avidity NanoMedicines, a biopharmaceutical company pioneering development of the Antibody-siRNA Complex (ARC™) as a new therapeutic class, announced today the issuance of two new U.S. patents. ARCs™ combine the potency and specificity of biologics with a nucleic acid-based payload, representing a breakthrough approach to the targeted delivery of nucleic acid-based medicines.

18 Jun 2014

New Report on Nanoparticle Drug Delivery Market

Research and Markets has announced the addition of the "Nanoparticle Drug Delivery Market & Clinical Pipeline Insight" report to their offering.

From Research and Markets 18 Jun 2014

Novel Nanoshell Protects Foreign Enzymes That Starve Cancer Cells

Nanoengineers at the University of California, San Diego have developed a nanoshell to protect foreign enzymes used to starve cancer cells as part of chemotherapy. Their work is featured on the June 2014 cover of the journal Nano Letters.

18 Jun 2014

Proposal Involving Radiotherapy and Nanoparticles for Breast Cancer Treatment Wins $100,000 Grant

On June 7, multidisciplinary researchers from across UC campuses came together at the Kingsgate Marriott Conference Center to develop new collaborations and research ideas in a unique competition.

13 Jun 2014

New Nanoparticle-Based Cancer Measurement Instrument Delivered to M.D. Anderson Cancer Center

Manhattan Scientifics, Inc. announced today that it has delivered its break-through, cancer measurement instrument to The University of Texas M.D. Anderson Cancer Center in Houston, TX.

From Manhattan Scientifics Inc. 11 Jun 2014

Researchers Employ CryoTEM to Image Dendrimer-Based Vesicles

One of the defining features of cells is their membranes. Each cell’s repository of DNA and protein-making machinery must be kept stable and secure from invaders and toxins. Scientists have attempted to replicate these properties, but, despite decades of research, even the most basic membrane structures, known as vesicles, still face many problems when made in the lab. They are difficult to make at consistent sizes and lack the stability of their biological counterparts.

11 Jun 2014

Cerulean's Lead Candidate Presented in Talk on Nanoparticle Delivery at ASCO Annual Meeting

Cerulean Pharma Inc., a leader in Dynamic Tumor Targeting™, today announced that Mark E. Davis, Ph.D., Professor of Chemical Engineering at the California Institute of Technology, presented information about Cerulean's lead candidate, CRLX101, in a presentation entitled "Nanoparticle Delivery Platform for Solid Tumors" at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago on Monday, June 2nd.

From Cerulean Pharma 11 Jun 2014

UCSB Researchers Design Novel Silver Nanoparticle for Efficient Drug Delivery

Scientists at UC Santa Barbara have designed a nanoparticle that has a couple of unique — and important — properties. Spherical in shape and silver in composition, it is encased in a shell coated with a peptide that enables it to target tumor cells. What's more, the shell is etchable so those nanoparticles that don't hit their target can be broken down and eliminated. The research findings appear today in the journal Nature Materials.

9 Jun 2014

Avidity NanoMedicines’ Scientific Co-Founder to be Honored with Coveted Award

Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research.

9 Jun 2014